Compare Amphastar Pharmaceuticals Inc (AMPH) vs J M Smucker Co (SJM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs J M Smucker Co — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while J M Smucker Co trades at $111.64 (market cap $11.93B). The key difference: J M Smucker Co is far larger — about 14.4× Amphastar Pharmaceuticals Inc's market cap, and J M Smucker Co pays a 3.94% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SJM | |
|---|---|---|
Market Cap | $826.08M | $11.93B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $117.05 |
52-Week Low | $16.87 | $89.53 |
Enterprise Value | $1.22B | $18.96B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SJM trades at $111.60, up 0.66% today, with technical indicators showing a bearish bias despite recent earnings beats. The company reported a net loss of $1.23 billion in 2025, though revenue grew to $8.73 billion. Analyst consensus is bullish with a $122.92 price target, but weak profitability metrics and high debt levels pose challenges. Recent news highlights mixed sentiment, with some outlets praising growth potential while others caution on sales pressure.
The outlook hinges on margin recovery in coffee and growth in Uncrustables, but fiscal 2027 sales guidance of a 3-4% decline tempers optimism. Risks include competitive pressures and debt management, while the 4% dividend yield offers income support. Upside depends on execution against muted growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
